Loading...
 
Mediterr J Rheumatol 2019;30(3):177-85
Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817)
Authors Information
1Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
2Academic Clinical Fellow, Rheumatology Unit, D' Internal Medicine Department, Hippokrateion University Hospital, Thessaloniki, Greece
3Research Fellow, Division of Clinical Immunology, 1stInternal Medicine Department, AHEPA University Hospital, Thessaloniki Greece
4Private Practice, Greece 
5Roche Hellas, Marousi, Greece
6Iaso General Hospital, Athens, Greece
References
  1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6. [https://doi.org/10.1016/j.autrev.2004.09.002] [PMID: 15823498]
  2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15. [https://doi.org/10.1136/annrheumdis-2015-207524] [PMID: 25969430] [PMCID: PMC4717393]
  3. Hunter CAJones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16(5):448-57. [https://doi.org/10.1038/ni.3153] [PMID: 25898198]
  4. Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012;12:1277-89. [https://doi.org/10.1517/14712598.2012.707178] [PMID: 22849354]
  5. Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013;45:357-63. [https://doi.org/10.3109/07853890.2013.771986] [PMID: 23650978]
  6. Emery P, Keystone E, Tony HP, Cantagrel A, Van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. [https://doi.org/10.1136/ard.2008.092932] [PMID: 18625622] [PMCID: PMC3811149]
  7. Genovese MC, Mckay JD, Nasonov EL, Mysler EF, Da Silva Na, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80. [https://doi.org/10.1002/art.23940] [PMID: 18821691]
  8. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. [https://doi.org/10.1016/S0140-6736(08)60453-5] [PMID: 18358926]
  9. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. [https://doi.org/10.1136/ard.2008.105197] [PMID: 19297346] [PMCID: PMC3747519]
  10. Drosos AA, Moutsopoulos HM. Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Clin Experimental Rheumatol 1995;13 Suppl 12:S7-12. [PMID: 8846545]
  11. Drosos AA, Lanchbury JS, Panayi GS, Moutsopoulos HM. Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum 1992;35:745-8. [https://doi.org/10.1002/art.1780350705] [PMID: 1622412]
  12. Notario Ferreira I, Ferrer Gonzalez MA, Morales Garrido P, González Utrilla A, García Sanchez A, Soto Pino MJ, et al. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice. Reumatol Clin 2017;13:78-84. [https://doi.org/10.1016/j.reuma.2016.03.014] [PMID: 27174398]
  13. Romao VC, Santos MJ, Polido-Pereira J,Duarte C, Nero P, Miguel C, et al. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. Biomed Res Int 2015;2015:279890. [https://doi.org/10.1155/2015/279890] [PMID: 26000286] [PMCID: PMC4427085]
  14. Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017;36(10):2187-92. [https://doi.org/10.1007/s10067-017-3779-2] [PMID: 28776300]
  15. Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, et al. Multicenter cross-sectional study of patients with rheumatoid arthritis in Greece: Results from a cohort of 2.491 patients. Mediterr J Rheumatol 2018;29(1):27-37. [https://doi.org/10.31138/mjr.29.1.27]
  16. Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90. [https://doi.org/10.1136/ard.2011.152678] [PMID: 21875873] [PMCID: PMC3184242]
  17. Iking-Konert C, Von Hinuber U, Richter C, Schwenke H, Gürtler I, Kästner P, et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology (Oxford) 2016;55:624-35. [https://doi.org/10.1093/rheumatology/kev372] [PMID: 26515959]
  18. Bykerk VP, Ostor AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4. [https://doi.org/10.1136/annrheumdis-2011-201087] [PMID: 22615456] [PMCID: PMC3595980]
  19. leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216-22. [https://doi.org/10.1136/ard.2010.140129] [PMID: 21551512]
  20. Forsblad-D'elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford) 2015;54:1186-93. [https://doi.org/10.1093/rheumatology/keu455] [PMID: 25505001]
  21. Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, et al. Effectiveness of tocilizumab with and without synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis 2016;75:1336-42. [https://doi.org/10.1136/annrheumdis-2015-207760] [PMID: 26374404] [PMCID: PMC4941183]
  22. Khilfeh IGuyette EWatkins JDanielson DGross DYeung K. Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study. J Manag Care Spec Pharm 2019;25(4):461-7. [https://doi.org/10.18553/jmcp.2019.25.4.461] [PMID: 30917076]
  23. Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study. Rheumatol Int 2014;34:25-33. [https://doi.org/10.1007/s00296-013-2866-1] [PMID: 24057144]
  24. Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, et al. Tocilizumab as Monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four–week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013;65(3):362–71. [https://doi.org/10.1002/acr.21847] [PMID: 22972745]